BECTON DICKINSON & CO 8-K

What Happened

• Becton Dickinson & Co (BDX) filed an 8-K reporting that, effective October 1, 2025, it reorganized its operations into five worldwide reportable business segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional and BD Life Sciences. The reorganization did not change the principal product lines of any unit.
• The company noted that on July 13, 2025 it entered a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation. After that separation/combination, the Life Sciences segment will be eliminated and BD’s segment reporting will consist of the remaining four segments.
• To help investors, BD furnished Exhibit 99.1: unaudited recast historical segment revenues for fiscal year 2025 and its quarterly periods, presented under the new segment structure. The exhibit includes certain non‑GAAP measures and adjustment schedules.

Key Details

• Effective date of reorganization: October 1, 2025.
• New reportable segments: Medical Essentials; Connected Care; BioPharma Systems (formerly Pharmaceutical Systems); Interventional; Life Sciences (Diagnostic Solutions and Biosciences).
• July 13, 2025: definitive agreement to combine Biosciences and Diagnostic Solutions with Waters Corporation; Life Sciences segment will be removed from future BD segment reporting after that transaction.
• BD furnished recast FY2025 and quarterly revenue data (Exhibit 99.1) to present historical revenues on the new segment basis; the exhibit contains non‑GAAP metrics and is furnished (not “filed”) under the Exchange Act.

Why It Matters

• For investors, this changes how BD reports revenue and segment results going forward, affecting comparability of historical quarterly and annual revenue disclosures. The furnished recast revenue schedules are intended to make past performance easier to compare under the new structure.
• The announced combination of parts of Life Sciences with Waters will reduce BD’s future segment count and could shift the company’s revenue mix once completed. This 8-K does not include new earnings, guidance, or operational forecasts—only the segment reorganization and recast revenue disclosures.